Professor Renato D. Lopes, MD, MHS, PhD, is a Professor of Medicine within the Division of Cardiology at Duke University Medical Center, Durham, North Carolina, USA, and a Professor of Medicine within the Divisions of Internal Medicine and Cardiology at the Federal University of Sao Paulo, Sao Paulo, Brazil. He completed his clinical training at the Federal University of Sao Paulo and his cardiology fellowship at the Duke Clinical Research Institute (DCRI), serving as Chief Fellow for the research training program. After completing his fellowship, Dr Lopes served as an Assistant Professor within the Division of Cardiovascular Medicine, in the university’s Department of Medicine. He is currently the Director of Clinical Events Classification (CEC) and the Co-Director of the Integrated Clinical Events-Safety Surveillance Group. His primary research interests include investigating the impact and outcomes of atrial fibrillation complicating acute coronary syndromes. He also has an interest in novel antithrombotic therapies and in the discovery of new biomarkers in cardiology. Dr Lopes has led several national and international clinical trials and registries and has participated in clinical events committees (CECs) for many trials, serving as CEC Chair or Principal Investigator for several of these trials. Dr Lopes helped to establish the Brazilian Clinical Research Institute (BCRI), Sao Paulo, an academic research organisation (ARO), of which he is Executive Director. The BCRI works with other AROs worldwide to improve the health, care and quality of life of patients in Latin America. Dr Lopes also created the Brazilian Global Health Institute (BGHI) at the Federal University of Sao Paulo.
General Statement of Disclosure:
CONSULTING FEES/HONORARIA: Bayer(MODEST), Pfizer(SIGNIFICANT), Portola(MODEST), Daiichi Sankyo(MODEST), Medtronic(MODEST), Boehringer Ingleheim(MODEST), Bristol Myers Squibb(MODEST), GlaxoSmithKline(MODEST), Merck & Co., Inc.(MODEST), Sanofi-Aventis(MODEST) RESEARCH/RESEARCH GRANTS: Glaxo Smith Kline(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT), Medtronic(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), Pfizer Inc(SIGNIFICANT), Sanofi-Aventis(SIGNIFICANT)